The American Pharmacist Pfizer It is preparing to immediately request the emergency approval of its vaccine against covid-19, which has already exceeded the safety requirements set for its phase 3 trials, according to the company’s CEO, Albert Bourla, on Tuesday.
Bourla spoke this way in a forum organized by The New York Times and in another of the specialized health medium STAT News, after his company and its partner BioNTech announced on November 9 that the vaccine it is more than 90% effective.
Meet the requirements
“We are very close to requesting the emergency clearance& rdquor ;, said the main person in charge of the pharmaceutical company, who did not want to give a precise date for this expected step.
According to Bourla, Pfizer has already collected the safety data required by the health authorities, which require manufacturers to follow up for two months of at least half of the people who received the vaccine during phase 3 trials.
In the tests, which began last July, about 44,000 people have participated and, according to the companies, the vaccine has shown a effectiveness greater than 90% in participants with no previous evidence of infection.
Following the announcement by Pfizer and BioNTech, this Monday the biotech Modern released test results of its vaccine project, which point to an effectiveness of around 94%.
Bourla, on the STAT News forum, said he was relieved to learn that there is another successful vaccine and was confident that there is still more, since global demand It will exceed the capacity of any company.